Amyloid plaque is a known neurotoxin and hallmark of Alzheimer’s pathology. There are currently no drugs approved to treat the chronic neurodegenerative disease. Fighting the disease with antibodies is showing encouraging results by negating the neurotoxic damage left in the wake of beta-amyloid aggregation, according to a study published April 30 in the Journal of Neuroscience.

A negative florbetaben PET scan provides solid evidence to rule out amyloid pathology in the brain based on phase III trial data matched by histopathology. The research was presented Wednesday during the Emerging Sciences session of the American Academy of Neurology (AAN) annual meeting in Philadelphia.

June 7-11, 2014St. Louis, MO 

Today the American Academy of Neurology (AAN) will be presenting a leadership in neurology award to Ben Utecht, a National Football League champion who suffered a traumatic brain injury (TBI) that tackled his career in 2009.

Advanced gene sequencing has found a single genetic mutation essential for a brain disorder that has been plaguing Turkish families for centuries.

In the first trial of its kind, a new type of peptide receptor is being targeted in neuroendocrine tumor (NET) imaging, which could reveal previously hidden cancer, according to a study published April 17 in the Journal of Nuclear Medicine.

Data from multiple clinical trials for DaTscan (I-123 FP-CIT Ioflupane) using SPECT shows that the exam is very sensitive for detecting striatal dopaminergic deficits, according to a presentation during the American Academy of Neurology being held April 26 through May 3 in Philadelphia.

The first markets for newly FDA-approved Vizamyl (F-18 flutemetamol), designated for ruling out Alzheimer’s disease and other dementias, were announced during the annual meeting of the American Academy of Neurology this week in Philadelphia, according to a statement from its producer, GE Healthcare.